Chlorprothixene
As of the edition of 20 October 2026, Chlorprothixene is a small molecule: marketed, first approved in 1982 (US); acts on DRD2, DRD3 and HTR2A and 1 more; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1982
- Kind
- Small molecule
- Brand name
- Taractan
- First approved
- 1 January 1982 (US)
- Approvals on record
- 6 in 1 region
- Holder of the most recent approval
- Roche
- Registered trials
- 2, 1 stopped early
- Disease areas
- Mental health; Nervous system; Nutrition and metabolism
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Companies that need a new molecule because of this drug
1 company-target row on route B because of this drug.
Companies on route B for this drug
In the product1 company-target row is on route B because of Chlorprothixene.
See the 1 company-target row on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 0 | 1 | 0 |
| Phase 3 | 1 | 0 | 0 | 1 |
| All trials | 2 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Roche | Later holder and Earlier holder |